Banco Santander S.A. Buys 182,059 Shares of DexCom, Inc. (NASDAQ:DXCM)

Banco Santander S.A. increased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1,839.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 191,959 shares of the medical device company's stock after buying an additional 182,059 shares during the quarter. Banco Santander S.A.'s holdings in DexCom were worth $14,929,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in DXCM. Farther Finance Advisors LLC lifted its holdings in DexCom by 79.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,568 shares of the medical device company's stock valued at $172,000 after purchasing an additional 1,134 shares during the last quarter. Van ECK Associates Corp lifted its holdings in DexCom by 14.0% during the 3rd quarter. Van ECK Associates Corp now owns 20,191 shares of the medical device company's stock valued at $1,463,000 after purchasing an additional 2,475 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in DexCom by 8.6% during the 3rd quarter. QRG Capital Management Inc. now owns 15,697 shares of the medical device company's stock valued at $1,052,000 after purchasing an additional 1,248 shares during the last quarter. Comprehensive Financial Consultants Institutional Inc. lifted its holdings in DexCom by 13.5% during the 3rd quarter. Comprehensive Financial Consultants Institutional Inc. now owns 7,334 shares of the medical device company's stock valued at $492,000 after purchasing an additional 874 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new stake in DexCom during the 3rd quarter valued at $222,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Remove Ads

Insider Transactions at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,083 shares of company stock worth $3,309,794. Insiders own 0.30% of the company's stock.

DexCom Trading Down 2.1 %

Shares of NASDAQ:DXCM traded down $1.67 during midday trading on Friday, hitting $77.84. 3,861,055 shares of the stock were exchanged, compared to its average volume of 3,717,810. The stock has a market capitalization of $30.42 billion, a price-to-earnings ratio of 54.43, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The business's 50-day moving average price is $84.83 and its 200 day moving average price is $76.99. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on DXCM. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and raised their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and lifted their target price for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Finally, Citigroup raised their price target on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.